Iloperidone for Bipolar Disorder

"This trial, which was originally posted on 3/22/2021 and last edited on 3/24/2021, is currently searching for participants, as reported on clinicaltrials.gov."

"That is correct. The clinicaltrials.gov website lists this trial as actively recruiting patients. The trial was first posted on March 22, 2021 and was last updated on March 24, 2021. The study is looking for 400 patients from 3 different sites."

"Iloperidone's Phase 3 status indicates that, while more data is needed to confirm efficacy, there is enough evidence of safety from multiple rounds of testing. Therefore, it received a score of 3."

"400 individuals will be admitted into this study that aims to test the efficacy of a new treatment for bipolar I disorder. The age requirements for participants are between 18 and 65 years old."

"The age restrictions for this trial are that participants must have celebrated their 18th birthday, and have not yet reached their 65th birthday."

"There are currently two ongoing clinical trials studying iloperidone, both of which are in Phase 3. 4 medical facilities in total are conducting research on iloperidone, with a few based in Atlanta, Georgia."

"As of now, there are two ongoing studies involving iloperidone in 4 cities across 2 nations. The first recorded trial was completed in 2013 and involved 288 patients. That study reached Phase 3 approval and was sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. In the 7 years since the first study, 14 more iloperidone trials have been completed."